StockData
Psyence Biomedical Ltd. logo

Psyence Biomedical Ltd. (PBM) stock

PBMNasdaqPharmaceutical PreparationsFiscal year ends March 31Also trades as PBMWW
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jun 22, 2026Score 0/30
$4.12−0.10 (-2.37%)

Close on Oct 19, 2026Market cap –P/E –Yield –

Psyence Biomedical r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2026 it was $1.47M, up 328.6% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026Mar 31, 2026$1.47M+328.6%
FY2025Mar 31, 2025$342.17K-64.2%
FY2024Mar 31, 2024$954.59K-40.7%
FY2023Mar 31, 2023$1.61M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ3 2025Sep 30, 2025$357.44K–
Q2 FY2025CQ3 2024Sep 30, 2024$265.63K–

More Psyence Biomedical figures

See a number that looks wrong?